New Brand Reflects Company’s Biotech and Life Sciences Solutions

NEWARK, Del.–Strategic Diagnostics Inc. (Nasdaq: SDIX – News), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, today announced it will be doing business as SDIX (Strategic Diagnostics Inc. d/b/a SDIX).

The new SDIX name and logo are designed to better reflect the Company’s evolution from its historical beginnings as an industrial diagnostics products and antibody production company to a the company it is today, a biotechnology company, with all of its core capabilities and expanded expertise in developing and delivering a full suite of innovative immuno-solutions. The new name also aligns the company name with its website address and NASDAQ listing, making the company easier to find and connect too.

Commenting on the announcement, Mr. Fran DiNuzzo, President and CEO of SDIX said, “Over the last twenty years, Strategic Diagnostics Inc. has grown by delivering value and innovation to our customers. Over the past several years, the company has emerged as an innovative supplier of immune-solutions to new customers in the Life Science market. As such, the company has evolved beyond its name and brand.

Today, our company is much more than the original Strategic Diagnostics name or SDI logo represented. We are transforming SDI into a biotechnology company with a key focus on growth in the Life Science and Food Safety markets. We intend for SDIX and our updated logo to symbolize our commitment to be experts at creating advantage for our customers and partners using quality, innovative, and effective immuno-solutions.”

About SDIX

SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the Pharmaceutical, Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has developed antibodies which advance its customers’ immuno-based work – reducing time, labor, and costs while increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis. For more information, visit www.sdix.com.

This news release may contain forward-looking statements reflecting SDI’s current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI’s public filings with the U.S. Securities and Exchange Commission.